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1. Introduction 
Breast cancer is one of the leading causes of death world-
wide and is forecasted to increase by over 50% from 283 000 
in 2011 to 441 000 in 2030 in the United States.1 Recent studies 
have demonstrated that tumor microenvironment (TME) plays an 
important role in neoplastic transformation, tumor growth and 
invasion, and therapeutic resistance.2−4 TME components com-
posed of stromal cells such as fibroblasts, mesenchymal stem 
cells (MSCs), and immune cells provides a supportive niche that 
promotes the growth and invasion of tumors and is believed to 
modulate drug responsiveness.5−7 The intercellular communica-
tion between tumor cells and stromal cells occurs via direct con-
tact and paracrine signaling through the recruitment of growth 
factors, cytokines, and chemokines.8−10 Together, these modes of 
communication are believed to mediate tumor expansion, inva-
sion, metastasis, and angiogenesis. Several studies demonstrate 
direct involvement of stromal cells like fibroblasts, normal epi-
thelial cells, and MSCs in progression of tumorigenesis and me-
tastasis.5−7 However, the exact role of different stromal cells in 
the TME, their interaction with each other and with the cancer 
cell in the progression of tumor has not been fully delineated. 
Despite the importance of this cell−cell communication, the cur-
rent scientific understanding remains limited on the interaction 
between the tumor cells and the surrounding cells due to the lack 
of appropriate tumor models. 
In vivo models have been primarily used to study the in-
volvement of tumor−TME interactions in cancer.11−14 However, 
these models are proving to be insufficient, as they do not lend 
themselves as readily to rigorous mechanistic manipulations and 
quantitative analysis to maximize the information that can be 
obtained regarding the dynamics of cell−cell interactions. Xeno-
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Abstract 
In this study, we demonstrate a method for controlling breast cancer cells 
adhesion on polyelectrolyte multilayer (PEM) films without the aid of adhe-
sive proteins/ ligands to study the role of tumor and stromal cell interac-
tion on cancer biology. Numerous studies have explored engineering co-
culture of tumor and stromal cells predominantly using transwell coculture 
of stromal cells cultured onto coverslips that were subsequently added to 
tumor cell cultures. However, these systems imposed an artificial bound-
ary that precluded cell−cell interactions. To our knowledge, this is the first 
demonstration of patterned coculture of tumor cells and stromal cells that 
captures the temporal changes in the miRNA signature as the breast tu-
mor develops through various stages. In our study we used synthetic poly-
mers, namely poly(diallyldimethylammonium chloride) (PDAC) and sulfo-
nated poly(styrene) (SPS), as the polycation and polyanion, respectively, to 
build PEMs. Breast cancer cells attached and spread preferentially on SPS 
surfaces while stromal cells attached to both SPS and PDAC surfaces. SPS patterns were formed on PEM surfaces, by either capillary force lithogra-
phy (CFL) of SPS onto PDAC surfaces or vice versa, to obtain patterns of breast cancer cells and patterned cocultures of breast cancer and stromal 
cells. In this study, we utilized cancer cells derived from two different tumor stages and two different stromal cells to effectively model a heteroge-
neous tumor microenvironment and emulate various tumor stages. The coculture model mimics the proliferative index (Ki67 expression) and tumor 
aggressiveness (HER-2 expression) akin to those observed in clinical tumor samples. We also demonstrated that our patterned coculture model cap-
tures the temporal changes in the miRNA-21 and miRNA-34 signature as the breast tumor develops through various stages. The engineered co-
culture platform lays groundwork toward precision medicine wherein patient-derived tumor cells can be incorporated within our in vitro models to 
identify potential pathways and drug treatment regimens for individual patients. 
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graft animal models of human tumors are widely used as in vivo 
models for studying cancer metastasis and drug screening.15,16 
However, these models do not accurately recreate the various 
components of TME and do not allow direct observation of the 
tumor during the course of the treatment. There is an increas-
ing interest in the development of in vitro tumor models due to 
the ease of manipulation and shorter time frame compared to 
an in vivo model.17−20 However, given the complexity of breast 
tumor, the challenge of designing an effective in vitro model is 
huge. Tumor tissues, the commonly used in vitro model, lack 
many characteristics of intact tumor, such as TME and metabolic 
demand. Although great effort has been put into developing in 
vitro human tumor models as well as 2D and 3D gel culture sys-
tems to model TME, significant hurdles remain.19−21 One major 
limitation of the current models is that they fail to combine dif-
ferent types of cells, or establish cocultures of tumor cells with 
stromal cells in vitro. Random and transwell cocultures are com-
monly used to study the role of cell−cell interactions in cancer 
invasion.22,23 These approaches are limited by poor reproducibil-
ity leading to inconsistent results. They also do not account for 
the physical contact between the cells that is established when 
the tumor cells recruit the stromal cells. Therefore, alternative in 
vitro platforms are necessary to study the interaction of cancer 
cells with stromal cells. 
Recently, in vitro coculture models have been fabricated on 
nano/micropatterned surfaces using a variety of microfabrica-
tion techniques, ranging from photolithography, microcontact 
printing, dip-pen spotting, to inkjet printing.22,24−27 These result-
ing in vitro patterned coculture models serve as a platform for 
studying cell−cell communication in a controlled environment 
of spatially defined nano/microscale surface. This addresses the 
limitations associated with random coculture and transwell co-
culture methods by not only providing a robust and reproduc-
ible means of recreating cell−cell interactions but also account-
ing for both direct and paracrine modes of communication. Most 
of these microfabrication methods rely on approaches that uti-
lize adhesive proteins for cell attachment and a background sur-
face that resist that are modified later for the attachment of a 
second cell type.26−28 Although these techniques allow for rec-
reating the cellular microenvironment, the use of protein sub-
strates adds an artificial component not present in the TME and 
does not mimic physiologically relevant interactions. The current 
in vitro method is limited due to the requirement of specialized 
materials, devices, and extensive expertise. 
Herein, we report a robust, inexpensive, protein free method 
that utilizes polyelectrolyte multilayers (PEMs) and capillary 
force lithography (CFL) to generate patterned coculture mod-
els of breast cancer cells and stromal cells. PEMs have been 
shown to be excellent candidates for biomaterial applica-
tions.28−38 In our study, we used synthetic polymers, namely, 
poly(diallyldimethylammonium chloride) (PDAC) and sulfo-
nated poly(styrene) (SPS), as the polycation and polyanion, re-
spectively, to build the multilayers. The choice of SPS and PDAC 
was based on previous studies, wherein the latter material was 
shown to be resistant to attachment by primary hepatocytes,39 
smooth muscle cells,40 and primary neuronal cells,41 while SPS 
was cytophilic for all the cell types evaluated. We as well oth-
ers have previously shown that PEM surfaces utilizing PDAC and 
SPS also provide an ability to control the arrangement of multi-
ple cell types with subcellular resolution.24,25,35,39 This technique 
allows the formation of cell patterns with different shapes and 
sizes of tunable directional properties, recreating cell−cell inter-
actions in a highly controlled manner. In addition, since CFL is a 
variant of soft lithography, this method has key advantages, such 
as low cost, high-throughput, and the ability to pattern repro-
ducible macroscopic areas. In this study, we capitalized upon the 
differential cell attachment and spreading of breast cancer cells 
on different PEM surfaces to engineer patterned cocultures of 
breast cancer cells and stromal cells. To demonstrate the trans-
lational validity of our platform, we employed two developmen-
tally distinct human breast cell lines for coculture development: 
(1) BT474 (HER2+ invasive breast cancer cells to model invasive 
ductal carcinoma (IDC)) and (2) 21MT-1 (stable patient-derived 
metastatic breast cancer cells isolated from the metastatic pleu-
ral effusion to model invasive mammary carcinoma (IMC)). We 
also used two different types of stromal cells, mammary epithe-
lial cells (MCF10A) and mesenchymal stem cells (MSCs), to dem-
onstrate the versatility of our platform. Since MCF10A are non-
tumorigenic cells and MSCs have a significant role in metastasis, 
our platform provides an opportunity to study cell−cell interac-
tions in a heterogeneous TME, an inimitable property of cancer 
progression. We further illustrated that our in vitro breast tumor 
model is capable of staging the breast tumor dynamics and em-
ulating clinical relevant molecular pathways at different stages 
of tumor points. For this purpose, we utilized the coculture sys-
tem developed in this study and demonstrated that our platform 
simulated key clinical markers prominently used for tumor diag-
nosis, including tumor (HER-2) and proliferation (Ki67) markers. 
Also our platform mirrored the clinical conditions when probed 
for miRNA-21 and miRNA-34 expression. The development of 
such in vitro models that recapitulates the in vivo like signaling 
in tumor would be desirable to increase the drive toward preci-
sion medicine to identify key biomarkers for early diagnosis and 
novel therapeutic interventions. 
2. Materials And Methods 
2.1. Materials. Poly(diallyldimethylammonium chloride) (PDAC) (MW 
~ 100,000−200,000) as a 20 wt % solution, sulfonated poly(styrene) so-
dium salt (SPS) (MW ~ 70 000), sodium chloride, bovine serum albu-
min (BSA), PKH26 cell staining kit, carboxyfluorescein succinimidyl ester 
(CFSE), carboxyfluorescein diacetate succinimidyl ester fluorescent dyes 
(CFDSE), alpha-Minimum Essential Medium (α-MEM), sodium bicarbon-
ate (NaHCO3), and cholera toxin were purchased from Sigma-Aldrich 
Corporation (St. Louis, MO). Poly(dimethylsiloxane) (PDMS) from the Syl-
gard 184 silicone elastomer kit (Dow Corning, Midland, MI) was used for 
making stamps. DMEM/F12 medium, fetal bovine serum (FBS), horse se-
rum, penicillin−streptomycin, l-glutamine, 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES), nonessential amino acids, and sodium 
pyruvate were purchased from Life Technologies (Gaithersburg, MD). 
2.2. Cell Lines and Culture Conditions. Adipose-derived MSCs 
and MCF10A cells were purchased from American Type Culture Collec-
tion (ATCC). MSCs were maintained in MSCGM (Lonza) supplemented 
with growth factors provided with the kit, and MCF10A cells were main-
tained in phenol red free DMEM/F12 culture medium supplemented with 
NaHCO3 (1200 mg/L), 5% horse serum, insulin (10 μg/mL), penicillin G 
(100 U/mL), streptomycin (100 μg/mL), l-glutamine (2 mM), EGF (20 ng/
mL), hydrocortisone (500 ng/mL), and cholera toxin (100 ng/mL). HER-2 
overexpressed breast cancer cell lines, BT-474 and 21MT-1, were a kind 
gift from Dr. Hamid Band (UNMC, Omaha, NE). BT-474 cells were grown 
in complete MEM supplemented with 5% FBS, 1% L-glutamine, penicil-
lin G (100 U/mL), streptomycin (100 μg/mL), 20 mM HEPES, nonessen-
tial amino acids, and sodium pyruvate (complete α-MEM). 21MT-1 cells 
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were maintained in complete α-MEM, further supplemented with EGF 
(12.5 ng/mL) and hydrocortisone (1 ng/mL). All cells were maintained in 
the presence of 5% CO2 at 37 °C. 
2.3. Cell Adhesion on Polymer Surfaces. Polyelectrolyte multilay-
ers (PEMs) were built on tissue culture polystyrene surface (TCPS) using 
layer-by-layer assembly of PDAC and SPS polymers as described ear-
lier.24,25 The concentrations of the PDAC and SPS solutions were 0.02 and 
0.01 M, respectively, using repeating unit molecular weight. Both poly-
mers were dissolved in deionized (DI) water with 0.1 M concentration of 
sodium chloride followed by filtration through filter paper (pore size < 
25 μm). TCPS were treated with oxygen plasma for 5 min using a Har-
rick plasma cleaner (Harrick Scientific Corporation, Broading Ossining, 
NY). The plate was immediately inserted into a Carl Zeiss slide stainer 
to carry out the automated layer-by-layer assembly process. Briefly, the 
plate was first dipped into the PDAC solution for 20 min followed by 
two 5 min washing steps in DI water with agitation. The plate was then 
dipped in the SPS solution for 20 min followed by two 5 min washing 
steps in DI water with agitation. This process was repeated for either 10 
or 10.5 bilayers to form (PDAC/SPS)10
 with SPS as a topmost layer and 
(PDAC/SPS)10.5
 with PDAC as a topmost layer. Prior to cell culture, fab-
ricated surfaces were sterilized overnight under UV. Breast cancer cells 
were grown on SPS [(PDAC/SPS)10], PDAC [(PDAC/SPS)10.5] for 5 days. 
Cell morphology was assessed by optical microscopic images of the cells 
on different surfaces acquired with Axiovert40 Zeiss (Germany) inverted 
microscope for 5 days. 
2.4. Polydimethylsiloxane (PDMS) Mold Fabrication. PDMS molds 
were fabricated by combining the PDMS prepolymer (Sylgard 184, Es-
sex Chemical) and curing agent in an 8:1 w/w ratio. Following vigorous 
mixing, the mixture was degassed in a desiccator until bubbles were no 
longer visible and cast against a silicon master that contained a pattern 
of line channels. The PDMS was cured for 8 h in a 60 °C oven. After cool-
ing to room temperature, a sharp scalpel and tweezers were used to re-
move the PDMS from the master and cut into stamps capable of fitting 
within a well of a six-well plate (approximately 5 mm by 5 mm). Stamps 
were cleaned with ultrapure 18 MΩ cm Millipore water and soap, and 
then dried with compressed air before use. 
2.5. Fabrication of Patterned Surfaces by Capillary Force Lithog-
raphy (CFL). Line patterns were created on PEMs built on TCPS surfaces 
using CFL. Patterned PDMS molds (discussed previously) were activated 
with oxygen plasma for 1 min and placed pattern-down on the PEM-
coated substrate. Slight pressure was applied to the mold to ensure good 
contact. Ten μL of the polymer solution that possesses a charge oppo-
site to the last layer of the PEM was injected into the channel openings 
(i.e., PDAC for [(PDAC/ SPS)10] or SPS for [(PDAC/SPS)10.5]). The solution 
was drawn through the channels by capillary action, and the mold was 
undisturbed until solvent evaporation was completed. Once finished, the 
PDMS was carefully removed along the channel patterns. The surface 
was rinsed with DI water to remove excess polymer and dried at room 
temperature. To generate more complex grid patterns for potential tri-
cultures, CFL was repeated on the patterned substrate, positioning the 
PDMS mold at a 90-degree rotation. 
2.6. Characterization of Patterns. Generated patterns were visual-
ized using 6-carboxyfluorecein succinimidyl ester (CFSE), rhodamine B, 
and negatively charged carboxylated polystyrene microparticles. Fabri-
cated surfaces were incubated with CFSE or rhodamine B or microparti-
cles for 10 min at room temperature, followed by three washes with DI 
water. Fluorescent and phase contrast images of patterns were observed 
and captured using Axiovert40 Zeiss inverted microscope (Germany). 
2.7. Cell Staining and Coculture. For visualization of cell patterns, 
breast cancer cells and stromal cells were prestained prior to seeding on 
patterned substrates. Two different cell types were distinguished from 
one another by staining with carboxyfluorescein diacetate succinimidyl 
ester (CFDSE) dye (green) and PHK26 dye (red), respectively. Briefly, cells 
were trypsinized and washed with medium without serum. Cells were 
subsequently incubated in 10 μg/ mL CFDSE in PBS solution at a con-
centration of 1 × 107 cells/mL or in 2 × 106 M PKH26 in diluent C at a 
concentration of 1 × 107 cells/ mL for 10 min at room temperature. Both 
staining reactions were quenched with the addition of an equal volume 
of serum and washed three times with medium. After a final wash, the 
cell pellet was suspended in medium, and 0.5 × 106 breast cancer cells 
were seeded. On the following day, 0.2 × 106 MSCs or MCF10As were 
seeded. Fluorescent images of the cells patterns were acquired with Ax-
iovert40 Zeiss (Germany) inverted microscope before and after coculture. 
2.8. Western Blotting. Cells were washed three times with ice cold-
phosphate buffered saline (PBS) and scraped in RIPA buffer (100 mM 
Tris, 5 mM EDTA, 5% NP40, pH-8.0) containing protease inhibitors cock-
tail (PIC) and phenylmethylsulfonyl fluoride (PMSF) followed by 10 min 
incubation on ice with intermittent vortexing. Clear cell lysate from all 
coculture systems was obtained by centrifugation at 10 000 rpm for 10 
min at 4 °C and stored at −80 °C until use. Protein concentration was 
determined using Coomassie Plus Assay reagent purchased from Pierce 
(Rockford, IL). An am amount of 10 μg of total protein was separated by 
7.5% SDS-polyacrylamide gel electrophoresis and transferred to Immob-
ilon P membranes (Millipore, Ballerica, MA) using transfer buffer (25 mM 
Tris, 192 mM glycine, 10% methanol). Membranes were blocked with 5% 
skimmed milk for 3 h at room temperature (RT) thereafter membranes 
were incubated with primary antibodies for overnight at 4 °C. Anti-HER-2 
(1:1000), anti-Ki67 (1:1000), or anti-GAPDH (1:4000) primary antibod-
ies were used followed by incubation with corresponding horse perox-
idase-conjugated secondary antibodies (1:5000) at room temperature 
(RT) for 1 h. Signal was detected using ECL and exposure to ECL Hyper-
film (Pierce, Rockford, IL). Densitometry was performed using Image Stu-
dio Lite Software ver 4.0 (LI-COR Biosciences). 
2.9. miRNA Isolation and qRT-PCR. Total miRNAs were isolated 
from cells using the miRNeasy isolation mini-kit (Qiagen). Quality and 
quantity of isolated miRNAs were tested using a ND-1000 spectropho-
Figure 1. Breast cancer cells on 
polyelectrolyte multilayers. Selective 
adhesion of breast cancer cells on 
fabricated surfaces was determined 
by studying the growth of cells on 
PEMs for 5 days. Half TCPS was coated 
with (PDAC/SPS)10
 and other half with 
(PDAC/SPS)10.5
 making SPS and PDAC 
as the topmost surfaces, respectively. 
Adhesion of BT-474 (A) and 21MT-1 
(B) cells on PDAC and SPS surfaces 
after day 5 of culture show more 
attachment of cells on SPS surface. 
Scale bar is 500 μm.  
9994 Daverey ,  Brown,  & K idambi  in Langmuir  31 (2015) 
tometer (NanoDrop Technologies, Wilmington, DE). The Mir-X miRNA 
First-Strand Synthesis Kit (Clontech) was used for converting miRNAs into 
cDNA to enable specific miRNAs to be quantified by real-time PCR. The 
SYBR Advantage qPCR Premix (Clontech) and mRQ 3′ (Clontech) primer 
were then used in real-time qPCR, along with miRNA-specific 5′ prim-
ers, to quantify miR-21 and miR-34a in the cDNA. Sequences for miR-21 
and miR-34a 5′ primers were: 5′-TAGCTTATCAGACTGATGTTGA-3′ and 5′- 
TGGCAGTGTCTTAGCTGGTTGT-3′ respectively. Quantitative PCR for miR-
21 and miR-34a was performed in epgradient S Mastercycler (Eppen-
dorf) using a program: denaturation at 95 °C for 10 s, followed by 45 
cycles of 95 °C for 5 s and 60 °C for 20 s. At the end, one cycle for disso-
ciation curve was performed at 95 °C for 60 s, followed by 55 °C for 30 s 
and 95 °C for 30 s. Data were analyzed using comparative delta−delta Ct 
method described earlier for which an additional qPCR was performed 
using U6 snRNA controls provided in SYBR Advantage qPCR Premix kit.42 
3. Results 
3.1. Breast Cancer Cells on Polyelectrolyte Multilay-
ers. To investigate the effects of PEM films on breast can-
cer cells, we assessed the response of breast cancer cells over 
continuous culture (Figure 1). For this purpose we utilized 
poly(diallyldimethylammonium chloride) (PDAC) and poly(4- sty-
renesulfonic acid) (SPS) as the polycation and polyanion, respec-
tively, to build the PEM films. PDAC and SPS are strong polyelec-
trolytes, resulting in smooth, homogeneous and stable PEM films 
suitable for cellular studies.43−45 The combination of PDAC and 
SPS has been widely employed to construct PEMs, although less 
work on cell adhesion has been done on this pair of polyelec-
trolytes than on other pairs such as poly(acrylic acid)/polyallyl-
amine, PAA/PAH, or the more biomolecular poly(glutamic acid)/
polylysine, PGA/PLL. The choice of PDAC was based on our previ-
ous studies, wherein this material was shown to be cell-resistant 
for primary hepatocytes, neurons, and breast cancer cells.24,25,42 
Recent study has demonstrated that PEMs using PDAC and SPS 
resulted in quasi-spherical cell clusters and attributed this differ-
ential cell adhesion due to the presentation of surface charges 
in different conditions.35 The thin films used for the cell studies 
Figure 2. 
Characterization  
of patterns. 
(A) Schematic overview 
for employing PEMs and 
CFL to create patterned 
coculture platform of 
breast cancer cells and 
stromal cells. First, 10.5 
bilayers of PDAC and 
SPS were deposited to 
a substrate using layer-
by-layer deposition 
to generate PDAC as 
a topmost layer. SPS 
polymer was deposited 
through channels of 
PDMS stamp using 
capillary force to 
generate polymer 
patterns. Breast cancer 
cells were seeded on 
patterned surfaces 
followed by seeding of 
stromal cells on day 3 
to generate patterned 
coculture. 
(B) Dimensions of PDMS 
mold employed. 
(C) Characterization 
of polymer patterns 
generated using 
CFL. Patterns were 
characterized using 
green dye CFSE (i); red 
dye rhodamine B (ii). 
Scale bar is 200 μm. 
(D) Complex grid 
patterns visualized 
with CFSE (i, iii) and 
rhodamine B (ii, iv). Scale 
bar is 500 μm.  
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were free of adhesive proteins or ligands. We employed two de-
velopmentally distinct human breast cell lines for coculture de-
velopment: (1) BT474 (HER2+ invasive breast cancer cells) and 
(2) 21MT-1 (stable patient-derived metastatic breast cancer cells 
isolated from the metastatic pleural effusion). We have previ-
ously shown that breast cancer cells, BT-474 and SKBr3 cells, at-
tached more on SPS surfaces than PDAC.42 Figure 1 compares 
the morphology of breast cancer cells on PDAC and SPS surfaces. 
For the direct comparison of the cell adhesion, we coated half 
the TCPS with (PDAC/SPS)10 and other half with (PDAC/SPS)10.5 
making SPS and PDAC as the topmost surfaces, respectively. 
Both BT-474 and 21MT-1 had higher attachment on SPS surfaces 
compared to PDAC surfaces demonstrating the preferential at-
tachment of breast cancer cells on SPS over PDAC. We utilized 
this differential cell adhesion to develop patterned coculture of 
breast cancer cells with stromal cells.  
3.2. Patterned Culture of Breast Cancer Cells on PEMs. 
Figure 2A shows a schematic diagram of overall strategy we 
used to develop patterned coculture. For patterning with CFL, 
thin layers of polymers were deposited using layer-by-layer as-
sembly and a liquid prepolymer of PDMS was cast against a sil-
icon master to prepare a PDMS mold. PDMS is excellent mate-
rial for mold preparation because of its high permeability for air 
to permeate out of the mold during molding process, an im-
portant characteristic for high resolution patterning. In addi-
tion, PDMS chemical inertness, low surface tension, favorable 
mechanical and optical properties, and simple manufacturing 
make it compatible with CFL methods, yielding robust micro-
structures over substrates regardless of patterning materials. 
Since CFL relies on naturally occurring capillary force without 
use of any external force, it offers a number of advantages in fab-
ricating geometry-controllable, robust micro and nanostructures 
over a large area. Dimensions of patterns used for this study are 
shown in Figure 2B. Patterning of polymer occurs when a liquid 
wets capillary tubes and moves forward with lowering of free 
energy (Figure 2C). Fabricated patterns were then characterized 
with fluorescent dyes (negatively charged CFSE and positively 
charged rhodamine), and negatively charged microparticles. The 
charges of the dye and microparticles mediate the ionic interac-
tion on the surface, with the negatively charged macromolecules 
 
 
 
 
 
 
 
 
 
 
deposited on PDAC surfaces while the positively charged mac-
romolecules deposited on SPS surfaces. Our data illustrated that 
the SPS/PDAC micropatterns were successfully created on glass 
substrates with good coverage and well-defined edges (Figure 
2C). To further demonstrate the ability to recreate more complex 
microenvironment for cell−cell interaction, we fabricated intri-
cate patterns by repeating CFL, positioning the PDMS mold at a 
90-degree rotation. The stained patterns with CFSE and rhoda-
mine shows formation of complex patterns indicating the PDAC 
and SPS regions (Figure 2D).  
Figure 3 illustrates the attachment of breast cancer cells on 
PDAC and SPS patterns after one and 3 days of culture. When 
presented with the patterned surface, both BT-474 and 21- MT1 
adhered preferentially on the SPS regions resulting in patterns 
of breast cancer cells. On day 1, breast cancer cells attached 
preferentially on the SPS regions resulting in cell patterns. The 
breast cancer patterns attached and maintained their morphol-
ogy for the first few days, but by day 7 began to detach from 
the PEM surfaces due to overcrowding (data not shown). We fur-
ther optimized the media composition and identified 1:1 ratio 
of breast cancer cells and MSCs or MCF10A media as the best 
culture conditions for the coculture platform (Supporting Infor-
mation Figure 1).  
3.3. Patterned Cocultures of Tumor Cells with Stromal 
Cells. Figure 4 illustrates patterned cocultures of breast can-
cer  cells with stromal cells on PEM surfaces. We employed two 
developmentally distinct human breast cell lines for coculture 
development: (1) BT474 (HER2+ invasive breast cancer cells to 
model IDC) and (2) 21MT-1 (stable patient-derived metastatic 
breast cancer cells isolated from the metastatic pleural effu-
Figure 3. Patterned culture of breast cancer cells on PEMs. Breast cancer 
cells patterns on day 1 and day 3 of cultures. On day 3 of culture, breast 
cancer cells form clear patterns distinct from surround background. Scale 
bar is 500 μm.  
Figure 4. Patterned cocultures of tumor cells with stromal cells. BT- 474 
and 21MT-1 breast cancer cells were stained with green dye CFDSE prior 
to seeding cells on patterns. Stromal cells, MSCs and MCF10A, were 
stained with red dye, PKH26 dye. Left panel shows monochrome fluores-
cent images of BT-474 cells (A, D) and 21MT-1 cells (G, J). Middle panel 
shows monochrome fluorescent images of MSCs (B, H) and MCF10A (E, 
K). Right panel represents merged image of BT-474/MSCs (C); BT-474/
MCF10A (F); 21MT-1/MSCs (I); 21MT-1/MCF10A (L). Scale bar is 500 μm. 
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sion to model IMC). We also used two different types of stro-
mal cells, mammary epithelial cells (MCF10A) and mesenchymal 
stem cells (MSCs), to demonstrate the versatility of our platform. 
Since MCF10A are nontumorigenic cells and MSCs have a sig-
nificant role in metastasis, our platform provides an opportu-
nity to study cell−cell interactions in a heterogeneous TME, an 
inimitable property of cancer progression. The preferential at-
tachment of breast cancer cells to SPS surfaces enabled the use 
of this system as a template for patterned cocultures with stro-
mal cells on synthetic PEM surfaces. To distinguish two cell pop-
ulations in patterned coculture system, breast cancer cells were 
stained with CFDSE dye (green) and stromal cells were stained 
with PKH26 dye (red). Fluorescence images of breast cancer cells 
and stromal cells showed distinct patterns of breast cancer cells 
on day 4 in coculture (Figure 4). We examined the reusability of 
these patterns. The cells were removed from the patterns with 
trypsin-EDTA and washed with PBS to ensure that the cells were 
completely removed from the patterned surfaces. A fresh batch 
of breast cancer cells was subsequently seeded onto the reused 
patterns and resulted in the formation of the patterns again 
(data not shown). 
3.4. Coculture Emulates Tumor Progression. To further val-
idate our model at functional level, we investigated the changes 
in key clinical markers prominently used for tumor diagnosis, in-
Figure 5. Coculture 
emulates tumor 
progression. 
(A) Upper panel 
shows representative 
immunoblot image 
of protein expression 
of Ki67 in BT-474 
and 21MT-1 breast 
cancer cells (BCCs) 
cocultured with MSCs 
and MCF10A cells. 
Lower panel shows 
densitometry analysis 
of bands normalized 
with respective BCCs 
monocultures. ***p 
< 0.001 vs BCCs 
monoculture. 
(B) Upper panel 
shows representative 
immunoblot image of 
protein expression of 
HER-2 in BT-474 and 
21MT-1 breast cancer 
cells cocultured with 
MSCs and MCF10A 
cells. Lower panel 
shows densitometry 
analysis of bands 
normalized with 
respective BCCs 
monocultures. ***p 
< 0.001 vs BCCs 
monoculture.  
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cluding tumor and proliferation in our coculture platform (Fig-
ure 5). Western blot analysis was performed on the coculture of 
breast cancer cells BT-474 and 21MT-1 with MSC and MCF10A 
to study tumor progression and proliferative rates using HER2 
and Ki67 as respective markers with mono culture of breast can-
cer cells and MSCs as controls. Previously, MSCs have been dem-
onstrated to induce increase proliferation and tumor growth 
of breast tumor.8−10 Since, MCF10A are normal mammary ep-
ithelial cells, no change in proliferation is anticipated. Our data 
showed a significant upregulation of Ki67 protein expression in 
cocultures of breast cancer cells with MSCs, while no significant 
change was observed in cells in transwell coculture, and mono-
cultures of breast cancer cells and MSCs indicating that the direct 
cell−cell contact is key to this phenomenon (Figure 5A). Further-
more, no significant increase in Ki67 expression was observed in 
breast cancer cells in coculture with MCF10A cells, suggesting 
the role of MSCs in tumor progression. Furthermore, a signifi-
cant upregulation of HER-2 protein expression was observed in 
cocultures of breast cancer cells with MSCs (Figure 5B) but not in 
transwell cocultures of breast cancer cells/MSCs and cocultures 
of breast cancer cells/MCF10A. Such changes are indicative of a 
net increase in cell growth (vs. apoptosis) and development of 
an aggressive tumor that would be consistent with the morpho-
logic transition in both the IDC and IMC stages. In the compari-
son between BT474/MSCs coculture (IDC-like) and 21MT1/MSCs 
coculture (IMC-like), HER-2 expression was significantly higher in 
the IMC model. These results demonstrate that the breast cancer 
cells in the IMC model indicated increase in tumor malignancy, 
which is similar to the transition observed in the clinical testing 
of IDC and IMC tumor samples.46−52 
3.5. Coculture Emulates miRNA Profiles of Clinical Condi-
tions. Microarray analysis on BT474/MSC and 21MT1/MSC co-
culture models showed that several miRNAs, including miRNA-21 
and miRNA-34a, were regulated (data not shown). Clinical stud-
ies have shown that miRNA-21 is upregulated in all pathways in 
breast cancer and plays an important role in deregulating many 
genes leading to the development of breast cancer.53−55 miRNA-
34a, a tumor suppressor miRNA, was reported to have significant 
influence on cell cycle, proliferation, migration, invasion, and self-
renewal in breast cancer cells.56−58 qRT-PCR on BT474/MSCs co-
culture and 21MT1/MSCs coculture was performed to validate 
the microarray data and profile the miRNA expression in the two 
breast cancer models with monoculture of breast cancer cells and 
MSCs as controls (Figure 6). The expression levels of miR-21 were 
increased in both coculture models while the expression levels of 
miR-34a were decreased in IDC coculture model compared to a 
monoculture of breast cancer cells. This data is representative of 
the miRNA expression trend observed in clinical breast tumor tis-
sues. The coculture model mimics breast cancer progression and 
shows stage-specific miRNA expression patterns. 
4. Discussion 
Breast cancer continues to be a major focus of medical re-
search due to its extensive socioeconomic impact. The major-
ity of the studies directly target tumor cells; however, the clinical 
success of these studies to develop mechanistic understand-
ing and antitumor therapies remains limited. Recently, can-
cer cell−stromal cell communications are strongly believed to 
play a significant role in cancer initiation, progression, and drug 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsiveness.5−7 Here, we report the development of patterned 
cocultures of breast cancer cells and stromal cells as in vitro 
models of breast tumors. Our in vitro platform is capable of rec-
reating the dynamics of various stages of breast tumors. Com-
munication between breast cancer cells and stromal cells has 
been widely recognized to play an important role in cancer ini-
tiation, promotion, progression, and development of resistance 
to treatment.5−7 Cancer cells maneuver the TME to favor cancer 
progression and metastasis by influencing stromal cells and the 
ECM.59−62 On the other hand, the stromal cells such as MSCs and 
epithelial cells carry the local tissue architectural cues and influ-
ence the cancer behavior.63−65 Animal experiments have made 
a significant contribution to understanding human diseases, in-
cluding breast cancer.11−14 However, they lack the ability to in-
tercept communication signals and to create snapshots of dif-
ferent tumor stages in order to better predict the effectiveness 
of treatment strategies in clinical settings. The in situ coculture 
model developed in this study allows interaction between stro-
mal cells (MSC, MCF10A) and tumor cells in a controlled mi-
croenvironment and emulates the temporal progression of the 
diseases, especially the evolution of genetic morphosis. The sig-
nificant advantages of our platform are (1) the protein-free cell-
culture environment reduces nonspecific function; (2) the phys-
ical contact between stromal cells and cancer cells established 
in our platform facilitates to investigate the role of direct cell−
cell interaction in tumor biology; and (3) the cancer−stromal cell 
interaction can be controlled by pattern dimensions to emulate 
different stages of a breast tumor. This platform further demon-
Figure 6. Coculture emulates miRNA profiles of clinical conditions. (A) 
Relative gene expression of miR-21 in BT-474 and 21MT-1 breast can-
cer cells (BCCs) cocultured with MSCs after normalization with respec-
tive BCCs monocultures. *p < 0.05 vs BCCs monoculture; ***p < 0.001 vs 
BCCs monoculture. (B) Relative gene expression of miR- 34a in BT-474 
and 21MT-1 breast cancer cells cocultured with MSCs after normaliza-
tion with respective BCCs monocultures. **p < 0.01 vs BCCs monoculture. 
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strates the capability of our in vitro coculture model to recapitu-
late the trends observed in clinically relevant biomarkers (HER-2 
and Ki67 expression).46−52 We also demonstrate that our cocul-
ture platform mimics the miRNA- 21 and miRNA-34a expres-
sion observed in clinical breast tumor samples.56−58,66−68 To our 
knowledge, no study has specifically investigated and demon-
strated the role of stromal cells in regulation of miRNA expres-
sion in breast cancer. Our in vitro platform replicates the clini-
cally observed trend with markers implicated to tumor stages 
and biology. 
The advent of new approaches and diagnostic tests has led 
to validating Ki67 and HER-2 as important prognostic and pre-
dictive markers. Ki67 is a nuclear nonhistone protein, and an 
antigen associated with cell proliferation and a strong correla-
tion has been found between the percentage of cells positive 
for Ki67 and nuclear grade, age, and mitotic rate in breast can-
cer.46,47 Cheang and co-workers demonstrated that immunopanel 
of HER2 and Ki67 can segregate the luminal A and B subtypes of 
breast cancers.48 This clinical study indicated that a differential 
Ki67 expression was suitable to discriminate between the sub-
types with higher expression classified as luminal B breast can-
cers having worse prognosis for both breast cancer recurrence 
and survival while lower expression classified as luminal A tu-
mors. Numerous studies have shown that breast cancers overex-
pressing Ki67 in more than 20%−50% of the cells are at high risk 
of developing recurrent disease, showing a statistically significant 
correlation with clinical outcome, such as disease-free survival 
or overall survival.46−49 HER2 plays an important role in promot-
ing oncogenic transformation and tumor growth.50−52 25%−30% 
of the breast cancer patients overexpress HER2 protein, and this 
overexpression is correlated with a poor clinical outcome.50−52 
Clinical studies have demonstrated that tumors with HER2 pro-
tein and gene overexpression showed a high concordance be-
tween the primary tumors and their metastases (97%).69 Ma-
jority of these studies have been performed in clinical patient 
tissues and animal models, however these are time-consuming 
and complicated to use the data for identifying the subtypes of 
the cancer. Our in vitro platform mimicked the clinical obser-
vations when the tumor cells were in direct contact with MSCs, 
where in the Ki67 and HER-2 protein expression was significantly 
(p < 0.001) higher compared to the tumor cells alone. Further-
more, this effect was not observed when the tumor cells were 
in direct contact with MCF10A cells. This demonstrates that our 
in vitro models can better represent the human tumors to in-
vestigate the underlying mechanisms of tumor progression be-
tween different subtypes and understand the role of stromal 
cells in the dynamic and heterogeneous behavior of cancers that 
mediates tumor progression and influences treatment response 
and outcomes. Our platform also paves way to Precision Med-
icine focusing on understanding complex interactions that are 
encountered but hard to dissect in clinical human samples while 
minimizing analysis times. 
Recent studies indicate that microRNA (miRNA) is an effective 
biomarker for a variety of diseases, including breast cancer.53−58 
MiRNA are a new class of RNAs that are involved in regulating 
mRNA expression at the post-transcriptional level and have an 
active role in gene regulation.70,71 Several of them are uniquely 
produced in cancer cells where they upregulate (or downregu-
late) the synthesis of certain proteins, leading to the formation of 
tumors. Microarray-based profiling of tumor samples from breast 
cancer patients found that miRNA-21 was consistently upregu-
lated in several types of breast cancer, suggesting a role for this 
miRNA in mammary tumor initiation or progression.66 Addition-
ally, miRNA-21 has also been identified as a marker for breast 
cancer and predictor of stage with higher expression at later 
stages of breast cancer.53−55 We demonstrated that miRNA-21 
expression is upregulated in both breast cancer cells cocultured 
with MSCs. Interestingly, we observed miRNA-21 expression 
was significantly higher in the 21MT1/MSCs coculture (IMC-like) 
compared to BT474/MSCs coculture (IDC-like). miRNA-21 has 
been found to be significantly higher in breast tumors with high 
proliferation index, advanced tumor staging, node involvement, 
and aggressive phenotype.53−55 Our coculture demonstrates a 
similar phenotype wherein we observe significantly higher Ki67 
expression in both IMC-like and IDC-like models which is indic-
ative of high proliferation index. Huang and co-workers showed 
that the miRNA-21 expression is correlated with HER- 2 upreg-
ulation and identified that miRNA-21 induces HER2- induced 
cancer cell invasion and miRNA-21 overexpression is a key phe-
notype in HER-2-positive breast cancer patients.72 These clinical 
results were emulated in our in vitro platform where we showed 
that the HER-2 expression is significantly upregulated in the co-
culture model which is indicative of advanced tumor staging and 
aggressive phenotype similar to the transition observed in the 
clinical testing of IDC and IMC tumor samples.56−58,66−68 MiRNA-
34a is a potent tumor suppressor and abrogation of miRNA-34a 
function could contribute to aberrant cell proliferation, leading 
to cancer development.56−58 Kato and co-workers demonstrated 
that low expression of miRNA-34a has been found in breast can-
cer cells.73 Roth and co-workers showed that circulating levels of 
miRNA-34a correlate with the presence of overt metastases in 
breast cancer patients.74 Peurala et al. have shown that miRNA-
34a acts as a tumor suppressor and when expressed exerts an in-
dependent effect for a lower risk of recurrence or death in breast 
cancer.75 This study observed low expression of miRNA-34a in 
about 32% and high expression in about 25% of the tumors. 
High miRNA-34a expression was correlated with an aggressive 
phenotype of breast tumors with high tumor grade and high 
proliferation rate of the tumors (IMC-like) while low expression 
of miRNA-34a was correlated with early stages of breast cancer 
(IDC-like). This indicates that miRNA-34a profile signature var-
ies with the stage of the breast cancer and this also might ex-
plain the discrepant data on the miRNA- 34a expression in di-
verse tumor entities that have been described. miRNA-34a has 
been reported to be downregulated in nonsmall cell lung car-
cinomas, pancreas tumor cell lines, colon carcinomas and pri-
mary neuroblastomas.76,77 In contrast, Dutta and co-workers ob-
served a high incidence of miRNA-34a overexpression in various 
tumor types.78 Consistent with the data of Peurala et al.,75 we de-
tected varying miRNA-34a levels in our coculture platform de-
pending on the source of the cells. BT474/MSCs coculture (IDC-
like) had a significant downregulation of miRNA-34a expression 
while 21MT1/MSCs coculture (IMC-like) had a slight upregula-
tion of miRNA-34a expression, thus indicative of the emulation 
of the corresponding tumor stages observed in clinical samples. 
In summary, we demonstrated an innovative approach to en-
gineer coculture of breast cancer and stromal cells, using the 
polyelectrolyte multilayers (PEM films) and capillary force li-
thography (CFL). This approach has several advantages over the 
method used by other groups. The advantages include its high 
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fidelity, ease of duplication, ability to provide topographical fea-
tures, ability to print a variety of molecules with nanometer res-
olution and without the need for dust-free environments and 
harsh chemical treatments. We have provided evidence that our 
platform emulates the different stages of the breast tumor by 
modeling IDC-like and IMC-like systems. To validate the mimicry 
of the clinical conditions, we demonstrated that the proliferative 
index (Ki67 expression) and tumor aggressiveness (HER-2 ex-
pression) in our coculture platform is similar to the clinical sam-
ples. Furthermore, we also demonstrated that our model pro-
vides the ability to capture the temporal change in the miRNA 
signature as the breast tumor develops through various stages. 
The key advantage of our coculture in situ breast tumor model 
is the ability to tailor the transitions between different stages 
of breast cancer by recreating and controlling the cell−cell in-
teractions in play as the breast tumor progresses. This platform 
provides a robust system to compare the temporal changes in 
miRNA expression to segregate the cancer subtypes. In the fu-
ture, this platform will provide an important tool for unlocking 
some of the intricacies of the miRNA-mediated molecular influ-
ences on early breast progression and potentially target specific 
processes to effectively stop breast cancer progression. The en-
gineered coculture platform also lays groundwork toward preci-
sion medicine where in patient-derived tumor cells can be incor-
porated within our in vitro models to identify potential pathways 
and drug treatment regimens for individual patients. 
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Supplementary Figure 1: Optimized culture conditions for the co-culture platform. (A) 
Upper panel, representative immunoblot shows expression of HER-2 as a marker for breast 
cancer cell to optimize media condition for co-culture of breast cancer cells with MSCs. Lower 
panel, densitometry analysis of bands shows no significant change in HER-2 expression when 
breast cancer cells (MEM/HE) and MSCs (MSCGM) media was used in 1:1 ratio. (B) Upper 
panel, representative immunoblot shows expression of HER-2 as a marker for breast cancer cell 
to optimize media condition for co-culture of breast cancer cells with MCF10A. Lower panel, 
densitometry analysis of bands shows no significant change in HER-2 expression when breast 
cancer cells (MEM/HE) and MCF10A (DMEM/F12) media was used in 1:1 ratio.  
 
